Nadofaragene Firadenovec

Summary

Nadofaragene Firadenovec (CHEMBL3990041) is a phase-3 clinical-stage gene (ATC L01XL10); indicated across 2 conditions including malignant pleural mesothelioma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• ATC class: L01XL10
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990041
Name	Nadofaragene Firadenovec
Type	Gene
Max phase	3
ATC	L01XL10

Also known as: Instiladrin, Nadofaragen firadenovec, Nadofaragene firadenovec, Nadofaragene firadenovec vncg, Nadofaragene firadenovec-vncg, rAd-IFN, rAd-IFN-2b, NADOFARAGENE FIRADENOVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
malignant pleural mesothelioma	3	MONDO:0005112	EFO:0000770

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	2
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06390111	PHASE4	WITHDRAWN	A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
NCT06510374	PHASE3	RECRUITING	Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06545955	PHASE3	RECRUITING	A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06929286	PHASE3	RECRUITING	A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT03710876	PHASE3	COMPLETED	Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
NCT06668493	PHASE1/PHASE2	RECRUITING	Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT07332351	PHASE2	NOT_YET_RECRUITING	Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
NCT01687244	PHASE2	COMPLETED	Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).